Globeflex Capital L P Invests $2.75 Million in Zevra Therapeutics, Inc. $ZVRA

Key Points

• Globeflex Capital initiated a $2.75 million position in Zevra Therapeutics, purchasing 191,904 shares, while institutional investors collectively own 35.03% of the company.
• Zevra reported quarterly earnings of $0.25 per share, beating estimates of $0.11, and revenue of $39.66 million versus the $33.88 million consensus forecast.
• Analysts maintain a favorable outlook, with nine Buy ratings and one Hold; the consensus rating is “Moderate Buy” with an average price target of $27.14, compared with the stock’s reported $11.87 price.

Globeflex Capital L P bought a new position in shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 191,904 shares of the company's stock, valued at approximately $2,752,000. Globeflex Capital L P owned about 0.32% of Zevra Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently bought and sold shares of the company. AIGH Capital Management LLC bought a new position in shares of Zevra Therapeutics during the 1st quarter valued at about $11,184,000. Dimensional Fund Advisors LP increased its holdings in shares of Zevra Therapeutics by 259.2% in the first quarter. Dimensional Fund Advisors LP now owns 554,802 shares of the company's stock worth $5,168,000 after purchasing an additional 400,336 shares during the last quarter. Hennion & Walsh Asset Management Inc. increased its holdings in shares of Zevra Therapeutics by 116.6% in the second quarter. Hennion & Walsh Asset Management Inc. now owns 383,706 shares of the company's stock worth $5,502,000 after purchasing an additional 206,543 shares during the last quarter. UBS Group AG lifted its position in shares of Zevra Therapeutics by 30.9% in the fourth quarter. UBS Group AG now owns 285,488 shares of the company's stock worth $2,558,000 after buying an additional 67,392 shares in the last quarter. Finally, Janney Montgomery Scott LLC lifted its position in shares of Zevra Therapeutics by 16.7% in the first quarter. Janney Montgomery Scott LLC now owns 236,834 shares of the company's stock worth $2,207,000 after buying an additional 33,951 shares in the last quarter. 35.03% of the stock is owned by hedge funds and other institutional investors.

Zevra Therapeutics Stock Performance

Shares of Zevra Therapeutics stock opened at $11.87 on Monday. The stock has a market cap of $704.84 million, a price-to-earnings ratio of 12.90 and a beta of 0.91. The stock has a 50 day moving average price of $12.23 and a 200-day moving average price of $10.77. Zevra Therapeutics, Inc. has a one year low of $7.16 and a one year high of $15.03.

Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) last released its quarterly earnings results on Wednesday, August 5th. The company reported $0.25 earnings per share for the quarter, beating the consensus estimate of $0.11 by $0.14. The company had revenue of $39.66 million for the quarter, compared to analyst estimates of $33.88 million. Zevra Therapeutics had a return on equity of 54.54% and a net margin of 42.82%. Sell-side analysts predict that Zevra Therapeutics, Inc. will post 0.72 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director Corey Michael Watton sold 12,300 shares of the stock in a transaction on Monday, August 10th. The shares were sold at an average price of $11.25, for a total value of $138,375.00. Following the sale, the director owned 1,800 shares of the company's stock, valued at approximately $20,250. This represents a 87.23% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 3.70% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on ZVRA shares. Citizens Jmp raised their price target on Zevra Therapeutics from $25.00 to $28.00 and gave the company a "market outperform" rating in a report on Thursday, August 6th. Canaccord Genuity Group decreased their price objective on Zevra Therapeutics from $29.00 to $20.00 and set a "buy" rating on the stock in a report on Monday, July 27th. Maxim Group increased their target price on Zevra Therapeutics from $25.00 to $35.00 and gave the company a "buy" rating in a research report on Wednesday, June 10th. Citigroup reissued an "outperform" rating on shares of Zevra Therapeutics in a report on Thursday, August 6th. Finally, Guggenheim decreased their price target on shares of Zevra Therapeutics from $24.00 to $23.00 and set a "buy" rating on the stock in a research note on Friday, August 7th. Nine analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $27.14.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source